4-Week Integrative Oncology Program

Two Powerful Therapies.
One Unified Strategy.

Cytotron RFQMR technology and NK Cell Immunotherapy work as a synchronized dual assault — one weakening the tumor's defenses, the other delivering precision immune firepower.

Schedule a Consultation ← Back to Main Site
28Day Protocol
6×NK Cell Infusions
35MNK Cells Per Dose
2-3 MoFirst Scan Timeline

"The idea of combining a tumor-stabilizing technology with an immune-boosting cell therapy is scientifically interesting and aligns with modern oncology trends — creating a continuous, overlapping anti-tumor assault designed to overcome tumor evasion."

The Two-Pronged Approach

Prime, Disrupt & Destroy

Each therapy targets cancer through a distinct mechanism — together, they create synergistic effects neither could achieve alone.

Therapy One

Cytotron RFQMR
The Tumor Disruptor

Rotational Field Quantum Magnetic Resonance technology delivers precisely focused, non-ionizing radiofrequency waves to destabilize cancer cells at the membrane level — halting division and triggering programmed self-destruction.

  • Disrupts Transmembrane Potential (TMP) of cancer cells
  • Reactivates the p53 tumor suppression pathway
  • Arrests cell cycle — stops cancer cell division
  • Induces apoptosis (programmed cell death)
  • Disrupts microtubule formation during mitosis
  • Non-invasive — no ionizing radiation, no DNA damage
  • Targets solid tumors by proton density via MRI mapping
Therapy Two

NK Cell Immunotherapy
The Immune Assassin

Infusions of 35 million allogeneic Natural Killer cells — expanded from umbilical cord blood — flood the system with precision immune fighters that directly identify and eliminate cancer cells, including circulating tumor cells that evade conventional treatment.

  • Recognizes "Missing Self" — targets cancer cells that hide from T-cells
  • Perforin/Granzyme pathway — punches pores into cancer cell membranes
  • FasL and TRAIL death receptor activation triggers caspase cascade
  • IFN-γ secretion activates macrophages and recruits T-cells
  • Hunts & eliminates Circulating Tumor Cells (CTCs) in the bloodstream
  • Prevents metastatic seeding — patrols lymphatics and organ sinusoids
  • Six infusions create a sustained, month-long immune surge
Deep Dive

How Cytotron
Works

The Cytotron uses Rotational Field Quantum Magnetic Resonance (RFQMR) technology — generating precisely focused beams of non-ionizing, non-thermal radiofrequency waves within a controlled magnetic field. Unlike radiotherapy, it does not use high-energy ionizing radiation that damages DNA.

Treatment is personalized using MRI to map the tumor's proton density — focusing RF energy specifically on cancer tissue while sparing surrounding healthy cells.

Step 1 — Targeting

MRI proton density mapping creates a personalized treatment plan. RF beams are precisely focused on tumor tissue only.

Step 2 — Membrane Disruption

RF waves alter the Transmembrane Potential (TMP) and Piezo 1 ion channels of cancer cells — disrupting the electrical signals that drive uncontrolled division.

Step 3 — p53 Reactivation

The treatment reactivates the p53 tumor suppressor pathway — the cell's master "stop" signal — which cancer had silenced to enable uncontrolled growth.

Step 4 — Apoptosis

Cancer cells receive the signal to self-destruct via natural apoptosis — the body's own orderly, inflammation-free cell disposal system. Cleared by the immune system over subsequent weeks and months.

FDA Breakthrough Device Designation
Cytotron holds FDA Breakthrough Device status for certain solid tumor indications — expediting clinical trial development for breast, liver, and pancreatic cancers. Currently available at select clinics outside the U.S.
Cytotron RFQMR device

The 28-Day Protocol

Days 1–10 · Phase One
Pain Relief & Stabilization
Many patients report a significant reduction in cancer-related pain, often reducing or stopping pain medication. Improved sleep and greater sense of well-being are common early responses.
Days 11–20 · Phase Two
Appetite & Energy Recovery
Appetite improves and patients begin to regain weight and energy. The tumor's growth is being arrested — cell division is slowing and apoptosis signals are building.
Days 21–28 · Phase Three
Tumor Stabilization
Primary goal: halt tumor progression and prevent further spread. Visible shrinkage on scans is a longer-term outcome as the body clears inactivated cells over the following months.
Months 2–3 · Post-Protocol
First Radiographic Assessment
First MRI/CT scan recommended 8–12 weeks after completing the protocol. Earlier scans may show pseudo-progression — immune infiltration that mimics tumor growth before true shrinkage becomes visible.
Consistency is Critical
A break of more than 24–48 hours in the Cytotron protocol may require restarting the entire 28-day cycle. The biological effects on cellular signaling are cumulative and time-sensitive.
Deep Dive

How NK Cell Therapy Works

Natural Killer cells deploy a multi-pronged, intelligent detection system and an arsenal of lethal mechanisms — and are especially powerful against circulating cancer cells that evade conventional treatment.

NK Cell IV Therapy

Target Recognition System

Missing Self Detection

Cancer cells often downregulate MHC Class I molecules to hide from T-cells — this makes them invisible to conventional immunity but a prime target for NK cells, which treat the absence of "self" markers as a kill signal.

Induced Self Activation

Cancer cells express stress ligands (MICA, MICB, ULBP) due to genomic instability. These engage NK cell NKG2D activating receptors — providing a direct "kill" signal that overrides inhibition.

Three Kill Mechanisms

Mechanism A — Perforin/Granzyme

The primary kill pathway. The NK cell forms a tight synaptic junction, releases cytotoxic granules — perforin punches pores in the cancer cell membrane, granzymes enter and activate caspase-dependent apoptosis from within.

Mechanism B — Death Receptor Pathway

NK cells express FasL and TRAIL ligands on their surface. Binding to cancer cell Fas and TRAIL-R receptors directly activates the caspase cascade — critical for killing chemotherapy-resistant cancer cells.

Mechanism C — Cytokine Warfare

IFN-γ inhibits cancer proliferation, normalizes tumor blood vessels to improve T-cell infiltration, and activates macrophages. TNF-α directly induces cancer cell death. Together they reshape the tumor microenvironment.

Solid Tumors vs. Circulating Cancer Cells

Against Solid Tumors

NK cells infiltrate the tumor, resist immunosuppressive signals (TGF-β, adenosine, Tregs), and target cancer stem cells and poorly vascularized zones that T-cells cannot reach. Their IFN-γ output is vital for disrupting the tumor's supportive stroma.

Against Circulating Tumor Cells (CTCs)

CTCs are stripped of the tumor's protective microenvironment and are maximally vulnerable. NK cells patrol the bloodstream and organ sinusoids — eliminating CTCs in transit and preventing metastatic seeding before secondary tumors can form.

Advanced NK Cell Science

Memory-like NK Cells

NK cells can develop adaptive immune features — longevity and enhanced recall responses — providing lasting anti-tumor memory.

Trogoptosis

A newly described mechanism: NK cells physically tear membrane pieces from cancer cells, causing direct lysis without conventional apoptosis signals.

Dendritic Cell Crosstalk

NK-derived IFN-γ matures dendritic cells, which activate tumor-specific T-cells — bridging innate and adaptive immunity for a full-system response.

ADCC Power

When tumor cells are coated with therapeutic antibodies, NK cells' CD16 receptor triggers Antibody-Dependent Cellular Cytotoxicity — a powerful targeted kill.

1–6hTime to cell death after NK hit
35MNK cells per infusion
6×Infusions over 28 days
The Synergistic Benefit

Why These Two Therapies
Are Stronger Together

The 28-day + 6 infusion schedule creates a sustained, overlapping attack designed to overcome tumor evasion, induce immunogenic cell death, and transition long-term immune control to your own body.

Synergy 1

Cytotron Exposes Targets for NK Cells

As Cytotron disrupts cancer cell membranes and alters their TMP, it upregulates stress ligands (MICA/B) on the cancer cell surface. These are exactly the signals NK cells look for — Cytotron effectively makes tumors more visible and vulnerable to NK attack.

Synergy 2

NK Cells Clear Cytotron-Weakened Cells

Cancer cells entering apoptosis or senescence from Cytotron treatment are in a distressed state. NK cells are specifically equipped to recognize and rapidly clear these stressed, dying cells — accelerating tumor clearance and reducing the inflammatory burden of cell debris.

Synergy 3

Dual Anti-Metastatic Protection

Cytotron arrests the primary tumor, preventing it from releasing new circulating tumor cells. Simultaneously, NK cells patrol the bloodstream, eliminating any CTCs already in circulation — creating a two-layer defense against metastatic spread.

Synergy 4

Immunogenic Cell Death Amplification

When cancer cells die via the combined protocol, they release tumor antigens in a way that educates the broader immune system. This process — immunogenic cell death — can trigger adaptive T-cell responses that extend protection long after the protocol ends.

Synergy 5

Overcoming Tumor Immune Evasion

Many tumors downregulate MHC-I molecules to evade T-cells — this is precisely what NK cells are designed to target. The combination ensures no evasion pathway goes unpunished: Cytotron disrupts biochemical evasion, NK cells exploit the resulting vulnerability.

Synergy 6

Sustained 28-Day Overlapping Assault

The protocols overlap intentionally: daily Cytotron sessions continuously destabilize new cancer cells while biweekly NK infusions maintain high immune pressure. The sustained nature of both prevents tumor adaptation or regrowth windows.

Combined Treatment Timeline

Days 1–28
Daily Cytotron
1 hour/day · 28 sessions · no breaks
Weeks 1–4
6× NK Infusions
35M cells each · approx. twice weekly · IV drip
Weeks 5–12
Immune Clearance
Body clears dead tumor cells · ongoing NK surveillance
Month 2–3
First MRI Assessment
8–12 weeks post-protocol · tumor size evaluated
Safety Profile

What to Expect

Cytotron — Reported Side Effects
  • Non-invasive — no ionizing radiation, no DNA damage
  • No chemotherapy-like fatigue, nausea, or myelosuppression reported
  • Minor, temporary skin redness or itching at treatment site in some patients
  • Long-term safety profile still being established through clinical trials
NK Cell Therapy — Potential Risks
  • Mild temporary fatigue, low-grade fever, or chills
  • Cytokine Release Syndrome (CRS) — monitored and managed on-site
  • Allergic reactions — emergency medical support available
  • Unknown interaction risks specific to this combined protocol
Important Note: This combined protocol is an experimental, research-stage approach. It is not a standard or FDA-approved therapy. Dr. Sosa personally reviews every patient case and maintains close coordination with your primary oncology team throughout the process. All decisions about treatment suitability are made on an individual basis following a thorough medical evaluation.
Begin Your Journey

Ready to Explore This Protocol?

Dr. Sosa personally reviews every case to determine whether this program may be right for you.

Schedule a Free Consultation ← Back to Main Site